← Back to patent-cliff list
盐酸噻氯匹定
Tier C — Watch / tradeTiclopidine Hydrochloride
罗氏
Originator
1978
First approval
-
Expiry (public)
No sales data
Peak sales
化学药
Type
Targets：P2RY12
Brand：Tiklyd、Ipaton、Tiklid、Ticlid、Ticlodix、Aplaket、Ticlodone、Panaldine
Indications (approved)：血栓栓塞、动脉闭塞性疾病、短暂性脑缺血发作、颅内血管痉挛、脑血管疾病、蛛网膜下腔出血
Regional status
US
撤市
EU
-
China
批准上市
1995-01-01
Japan
批准上市
1981-09-01
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Ticlopidine Hydrochloride?
Approved indications include: 血栓栓塞, 动脉闭塞性疾病, 短暂性脑缺血发作, 颅内血管痉挛, 脑血管疾病, 蛛网膜下腔出血.
When does the Ticlopidine Hydrochloride patent expire?
No public expiry year is available for Ticlopidine Hydrochloride yet; this page updates once verified.
How do I get a quote for Ticlopidine Hydrochloride intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-25